Culley Brian M 4
4 · Lineage Cell Therapeutics, Inc. · Filed Mar 12, 2026
Research Summary
AI-generated summary of this filing
Lineage Cell (LCTX) CEO Brian Culley Buys 15,000 Shares
What Happened
Brian M. Culley, President, CEO and a director of Lineage Cell Therapeutics, purchased 15,000 shares in open-market transactions on March 12, 2026. The reported weighted-average price was $1.63 per share, for a total reported outlay of $24,375. This was a purchase (transaction code P), which is a direct acquisition of common stock.
Key Details
- Transaction date: 2026-03-12 (filed the same day) — appears timely.
- Shares purchased: 15,000 shares.
- Reported price: weighted average $1.63 per share; total reported value $24,375.
- Footnote: the $1.63 is a weighted average; individual trade prices ranged from $1.61 to $1.63. The filer offers to provide a breakdown of the number of shares at each price on request (SEC footnote).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Transaction code: P = Purchase (open-market).
Context
Insider purchases are often regarded by investors as a potentially bullish signal because executives are buying company stock with personal funds, but the filing does not state the insider's motivation. This was a straightforward open-market buy (not an option exercise, gift, or award).
Insider Transaction Report
- Purchase
Common Shares
[F1]2026-03-12$1.63/sh+15,000$24,375→ 255,516 total
Footnotes (1)
- [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.61 to $1.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1.